EMEA-003008-PIP01-21
Table of contents
Key facts
| Active substance |
Virus-like particle of SARS-CoV-2 spike protein (recombinant, adjuvant) (CoVLP)
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0162/2022
|
| PIP number |
EMEA-003008-PIP01-21
|
| Pharmaceutical form(s) |
Suspension and emulsion for emulsion for injection
|
| Condition(s) / indication(s) |
Prevention of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Medicago Inc.
Email: atkinsj@medicago.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|